Protagonist Therapeutics, Inc. to Host Webcast and Conference Call
Newark, CA / ACCESSWIRE / November 19, 2024
Conference Call and Webcast Details
Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) has announced that they will be hosting a conference call and webcast to introduce their oral peptide IL-17 antagonist development candidate and to discuss in vitro and pre-clinical proof-of-concept study results. The event is scheduled for Thursday, November 21st at 4:30 pm ET.
The dial-in numbers for the investor update are as follows:
- US-based Investors: 1-877-407-0752
- International Investors: 1-201-389-0912
Conference Call ID: 13750274
The webcast link is here: Webcast Link
A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage after the event.
Protagonist Therapeutics is a company that is known for its innovative approach to drug development. Their focus on oral peptide IL-17 antagonists has the potential to revolutionize the treatment of certain diseases. IL-17 is a cytokine that plays a key role in inflammation, and targeting it with oral peptides could provide a more efficient and targeted treatment option for patients.
The upcoming conference call and webcast will be a key opportunity for investors and analysts to learn more about Protagonist’s development candidate and the promising study results. The company’s commitment to bringing novel therapeutics to market is evident in their intense focus on research and development.
How Will This Affect Me?
As an individual, the advancements in drug development by Protagonist Therapeutics could potentially benefit you in the future. The development of oral peptide IL-17 antagonists could lead to more effective and targeted treatments for various diseases, offering hope for improved health outcomes.
How Will This Affect the World?
The introduction of novel therapeutics like oral peptide IL-17 antagonists could have a significant impact on the field of medicine and healthcare worldwide. By addressing inflammation and targeting specific pathways, these advancements may pave the way for more personalized and effective treatments, ultimately enhancing patient care on a global scale.
Conclusion
Protagonist Therapeutics’ upcoming conference call and webcast represent a significant milestone in the company’s journey towards developing innovative treatments. The introduction of their oral peptide IL-17 antagonist development candidate has the potential to revolutionize the treatment landscape for various diseases, offering new hope for patients worldwide.
